“This quarter marked a significant inflection point for Allogene as we advance the streamlined ALPHA3 trial toward its next key milestone, initiate clinical enrollment in our first autoimmune indications with ALLO-329, and aligned with the FDA on a pivotal path forward for ALLO-316 in solid tumors,” said David Chang, president, CEO and co-founder of Allogene. “Our progress reflects a focused and disciplined execution strategy, and a clear path to value creation as we advance the next wave of scalable and accessible cell therapies with potentially durable results.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics options imply 16.7% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, August 13, 2025
- Is ALLO a Buy, Before Earnings?
- Strategic Adjustments and Technological Advancements Drive Buy Rating for Allogene Therapeutics
- Allogene Therapeutics: Strategic Adjustments and Positive Interim Data Justify Buy Rating